A systematic review of 39 randomized controlled trials (RCTs) found increased risks of vomiting, nausea, constipation, and diarrhea with GLP-1RAs in non-diabetic individuals compared to placebo
GHRP-6 produces notable cortisol, prolactin, and strong hunger stimulation alongside its GH pulse
Evidence-Based Complementary and Alternative Medicine , 2018 , 130
Work with pharmacy benefit manager (PBM) and manufacturer partners to negotiate down costs and enhance access
Patients considering low-dose GLP-1 therapy should undergo thorough evaluation, including assessment of contraindications, baseline inflammatory markers if appropriate, and regular monitoring for adverse effects
For patients meeting NICE criteria for weight management therapy (BMI 35 kg/m with adjustment for ethnicity, presence of weight-related comorbidities, and treatment through specialist weight management services), the dual benefit of weight reduction and blood pressure lowering may be particularly valuable